United Therapeutics Corporation $UTHR Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 18.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 146,163 shares of the biotechnology company’s stock after purchasing an additional 23,107 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in United Therapeutics were worth $79,204,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in United Therapeutics in the second quarter worth $2,868,735,000. Janus Henderson Group PLC lifted its position in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC purchased a new position in United Therapeutics during the second quarter valued at $450,140,000. Swedbank AB lifted its position in United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after buying an additional 2,350 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of United Therapeutics by 0.8% during the 1st quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock valued at $183,306,000 after buying an additional 2,383 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of a number of recent research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 target price on shares of United Therapeutics in a research report on Wednesday, October 14th. Morgan Stanley increased their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. UBS Group set a $725.00 price target on shares of United Therapeutics in a research report on Monday. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Finally, Leerink Partners boosted their price objective on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $651.21.

United Therapeutics Stock Up 1.7%

United Therapeutics stock opened at $563.49 on Thursday. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The company has a market capitalization of $24.17 billion, a P/E ratio of 20.16, a PEG ratio of 3.96 and a beta of 0.49. The stock’s 50 day moving average is $515.71 and its 200 day moving average is $539.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 earnings per share. As a group, equities analysts expect that United Therapeutics Corporation will post 26.40 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,587,119.60. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $543.32, for a total value of $5,161,540.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $176,276,370.76. This represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 401,528 shares of company stock worth $208,069,526. Insiders own 8.60% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their outlook. Leerink Partners increased its price target for United Therapeutics to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus remains bullish, with a “Moderate Buy” rating and an average target near $650, implying further potential upside. Leerink Partners Raises Price Target
• Positive Sentiment: United Therapeutics expanded its xenograft capacity. The company opened its third designated pathogen-free xenograft production facility in Houston, Texas. The facility supports its longer-term strategy of developing genetically modified organs for transplantation and may strengthen future growth opportunities beyond its pulmonary hypertension drug franchise. Third Xenograft Production Facility
• Neutral Sentiment: Third-quarter earnings are approaching. United Therapeutics will report financial results before the market opens on November 4. The release could provide an important update on demand for Tyvaso and other pulmonary hypertension treatments, margins, and progress in organ manufacturing. Third-Quarter 2026 Earnings Announcement
• Negative Sentiment: Insider selling presents a modest cautionary signal. CEO Martine Rothblatt reported sales of 9,500 shares in transactions dated October 16 and October 19, reducing her position by about 2.84% in each filing. The company’s general counsel also sold shares under a trading plan. Because the sales appear relatively small compared with Rothblatt’s remaining stake and were conducted under planned arrangements, they do not necessarily indicate deteriorating business prospects.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.